Literature DB >> 29098433

Effect of transanal total mesorectal excision for rectal cancer: comparison of short-term outcomes with laparoscopic and open surgeries.

Sharaf Karim Perdawood1, Benjamin Sejr Thinggaard2, Maya Xania Bjoern3.   

Abstract

OBJECTIVE: To compare short-term results of total mesorectal excision (TME) for mid and low rectal cancer, achieved by transanal (TaTME), laparoscopic (LaTME), and open (OpTME) approaches.
BACKGROUND: The impact of TaTME on the surgical treatment of mid and low rectal cancer has yet to be clarified.
METHODS: This is a case-matched study, based on data from a prospectively maintained database of patients who underwent TaTME from May 2015 to March 2017, and a retrospective chart review of patients who underwent LaTME and OpTME in the previous period. Each patient in the TaTME group was matched to one LaTME and one OpTME based on sex, BMI, tumor status, and the height of the tumor from the anal verge. Primary end-points were rates of positive circumferential resection margin (CRM), distal resection margin, and the macroscopic quality of the surgical specimen. Composite of these outcomes was compared as an indication for successful surgery. Secondary end-points included intraoperative data and postoperative course and complications.
RESULTS: Three hundred patients were included (TaTME = 100, LaTME = 100, OpTME = 100). The three groups were comparable in the baseline characteristics. TaTME resulted in lower rates of incomplete TME specimens than LaTME, but not OpTME (P = 0.016, P = 0.750, respectively). The rates of CRM involvement, mean CRM distance, and the percentages of successful surgery were comparable among the three groups (P = 0.368). The conversion to open surgery occurred only in the LaTME group. TaTME resulted in shorter operation time and less blood loss than the other two groups (P < 0.001 and P < 0.001). Hospital stay was shorter in the TaTME group (P = 0.002); complication rate and mortality were comparable among the groups.
CONCLUSIONS: TaTME had, in our hands, some obvious benefits over other approaches. The pathological results were not significantly superior to LaTME and OpTME. The procedure is however feasible and safe. Further studies are needed to evaluate the long-term oncological and quality of life outcomes.

Entities:  

Keywords:  Laparoscopy; Rectal cancer surgery; TaTME; Total mesorectal excision

Mesh:

Year:  2017        PMID: 29098433     DOI: 10.1007/s00464-017-5926-x

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  34 in total

Review 1.  Transanal Total Mesorectal Excision: The Work is Progressing Well.

Authors:  Andre D'Hoore; Albert M Wolthuis; Dana R Sands; Steven Wexner
Journal:  Dis Colon Rectum       Date:  2016-03       Impact factor: 4.585

2.  High Rate of Positive Circumferential Resection Margins Following Rectal Cancer Surgery: A Call to Action.

Authors:  Aaron S Rickles; David W Dietz; George J Chang; Steven D Wexner; Mariana E Berho; Feza H Remzi; Frederick L Greene; James W Fleshman; Maher A Abbas; Walter Peters; Katia Noyes; John R T Monson; Fergal J Fleming
Journal:  Ann Surg       Date:  2015-12       Impact factor: 12.969

3.  A new approach to rectal cancer.

Authors:  R J Heald
Journal:  Br J Hosp Med       Date:  1979-09

4.  Laparoscopic resection in rectal cancer patients: outcome and cost-benefit analysis.

Authors:  Marco Braga; Matteo Frasson; Andrea Vignali; Walter Zuliani; Giovanni Capretti; Valerio Di Carlo
Journal:  Dis Colon Rectum       Date:  2007-04       Impact factor: 4.585

5.  Transanal total mesorectal excision in rectal cancer: short-term outcomes in comparison with laparoscopic surgery.

Authors:  María Fernández-Hevia; Salvadora Delgado; Antoni Castells; Marta Tasende; Dulce Momblan; Gabriel Díaz del Gobbo; Borja DeLacy; Jaume Balust; Antonio M Lacy
Journal:  Ann Surg       Date:  2015-02       Impact factor: 12.969

6.  Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial.

Authors:  Pierre J Guillou; Philip Quirke; Helen Thorpe; Joanne Walker; David G Jayne; Adrian M H Smith; Richard M Heath; Julia M Brown
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

7.  Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997.

Authors:  R J Heald; B J Moran; R D Ryall; R Sexton; J K MacFarlane
Journal:  Arch Surg       Date:  1998-08

8.  Transanal vs laparoscopic total mesorectal excision for rectal cancer: initial experience from Denmark.

Authors:  S K Perdawood; G A A Al Khefagie
Journal:  Colorectal Dis       Date:  2016-01       Impact factor: 3.788

9.  The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?

Authors:  R J Heald; E M Husband; R D Ryall
Journal:  Br J Surg       Date:  1982-10       Impact factor: 6.939

10.  COLOR III: a multicentre randomised clinical trial comparing transanal TME versus laparoscopic TME for mid and low rectal cancer.

Authors:  Charlotte L Deijen; Simone Velthuis; Alice Tsai; Stella Mavroveli; Elly S M de Lange-de Klerk; Colin Sietses; Jurriaan B Tuynman; Antonio M Lacy; George B Hanna; H Jaap Bonjer
Journal:  Surg Endosc       Date:  2015-11-04       Impact factor: 4.584

View more
  27 in total

1.  Transanal total mesorectal excision: the Slagelse experience 2013-2019.

Authors:  Sharaf Karim Perdawood; Jens Kroeigaard; Marianne Eriksen; Pauli Mortensen
Journal:  Surg Endosc       Date:  2020-02-18       Impact factor: 4.584

2.  [Transanal total mesorectal excision : A useful complementary method for minimally invasive surgery of rectal cancer].

Authors:  A D Rink; F Aigner; M Biebl; A Fürst; W Kneist
Journal:  Chirurg       Date:  2019-06       Impact factor: 0.955

3.  Manometric assessment of anorectal function after transanal total mesorectal excision.

Authors:  M X Bjoern; S K Perdawood
Journal:  Tech Coloproctol       Date:  2020-02-01       Impact factor: 3.781

4.  Pathological outcomes of transanal versus laparoscopic total mesorectal excision for rectal cancer: a systematic review with meta-analysis.

Authors:  Hong-Peng Jiang; Yan-Sen Li; Bo Wang; Chang Wang; Fan Liu; Zhan-Long Shen; Ying-Jiang Ye; Shan Wang
Journal:  Surg Endosc       Date:  2018-02-20       Impact factor: 4.584

5.  A case of local recurrence following transanal total mesorectal excision: a new form of port-site metastasis?

Authors:  S K Perdawood
Journal:  Tech Coloproctol       Date:  2018-04-03       Impact factor: 3.781

6.  Meta-analysis of transanal total mesorectal excision versus laparoscopic total mesorectal excision in management of rectal cancer.

Authors:  Shahin Hajibandeh; Shahab Hajibandeh; Mokhtar Eltair; Anil T George; Vijay Thumbe; Andrew W Torrance; Misra Budhoo; Howard Joy; Rajeev Peravali
Journal:  Int J Colorectal Dis       Date:  2020-03-02       Impact factor: 2.571

7.  Quality of Life After Surgery for Rectal Cancer: a Comparison of Functional Outcomes After Transanal and Laparoscopic Approaches.

Authors:  Maya Xania Bjoern; Sarah Nielsen; Sharaf Karim Perdawood
Journal:  J Gastrointest Surg       Date:  2019-01-02       Impact factor: 3.452

8.  A comparative cost analysis of transanal and laparoscopic total mesorectal excision for rectal cancer.

Authors:  Francesca Di Candido; Michele Carvello; Deborah S Keller; Elena Vanni; Annalisa Maroli; Isacco Montroni; Roel Hompes; Matteo Sacchi; Marco Montorsi; Antonino Spinelli
Journal:  Updates Surg       Date:  2020-09-14

Review 9.  Transanal total mesorectal excision for rectal cancer: state of the art.

Authors:  David A Westwood; Tahleesa J Cuda; A E Ricardo Hamilton; David Clark; Andrew R L Stevenson
Journal:  Tech Coloproctol       Date:  2018-09-25       Impact factor: 3.781

10.  A randomized clinical trial comparing the initial vascular approach to the inferior mesenteric vein versus the inferior mesenteric artery in laparoscopic surgery of rectal cancer and sigmoid colon cancer.

Authors:  Pere Planellas; Helena Salvador; Ramon Farrés; Núria Gómez; David Julià; Júlia Gil; Marcel Pujadas; Franco Marinello; Lídia Cornejo; Antoni Codina
Journal:  Surg Endosc       Date:  2018-10-30       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.